Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study
Even in the era of novel targeted agents, switching to a second-line nonsteroidal antiandrogen (NSAA) is still widely used in treating metastatic castration-resistant prostate cancer (mCRPC), especially in undeveloped countries. However, whether prior treatment with a second-line NSAA would impact t...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Asian Journal of Andrology |
Subjects: | |
Online Access: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=6;spage=545;epage=550;aulast=Zhao |
id |
doaj-01191fd9f5a04877bf8f49db057f556a |
---|---|
record_format |
Article |
spelling |
doaj-01191fd9f5a04877bf8f49db057f556a2020-11-25T01:40:29ZengWolters Kluwer Medknow PublicationsAsian Journal of Andrology1008-682X1745-72622018-01-0120654555010.4103/aja.aja_58_18Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective studyJin-Ge ZhaoJian-Dong LiuPeng-Fei ShenXin TangGuang-Xi SunXing-Ming ZhangJun-Ru ChenKun-Peng ShuMing ShiHao ZengEven in the era of novel targeted agents, switching to a second-line nonsteroidal antiandrogen (NSAA) is still widely used in treating metastatic castration-resistant prostate cancer (mCRPC), especially in undeveloped countries. However, whether prior treatment with a second-line NSAA would impact the efficacy of abiraterone acetate (Abi) remains uncertain. In the current study, 87 mCRPC patients treated with Abi were analyzed. Among them, 21 were treated with a second-line NSAA (from bicalutamide to flutamide) before receiving abiraterone, while the remaining 66 received Abi directly. Therapeutic efficacy of Abi was compared between those with and without prior second-line NSAA using Kaplan–Meier curves, log-rank test, and Cox regression models. The therapeutic efficacy of Abi was similar between those with or without the prior switching treatment of flutamide, in terms of either prostate-specific antigen progression-free survival (PSA-PFS, 5.5 vs 5.6 months, P = 0.967), radiographic progression-free survival (rPFS, 12.8 vs 13.4 months, P = 0.508), overall survival (OS, not reached vs 30.6 months, P = 0.606), or PSA-response rate (71.4% [15/21] vs 60.6% [40/66], P = 0.370). This is the first time that the impact of prior switching of treatment to a second-line NSAA on the efficacy of Abi in mCRPC patients has been addressed. Our data support that, use of prior sequential bicalutamide and flutamide does not seem to preclude response to abiraterone, although larger cohort studies and, ideally, a randomized controlled trial are needed. These findings will facilitate doctors' decision-making in the treatment of mCRPC patients, especially for those with previous experience of switching NSAA second-line treatments in the clinic.http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=6;spage=545;epage=550;aulast=Zhaoabiraterone; antiandrogen; castration-resistant prostate cancer; flutamide |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jin-Ge Zhao Jian-Dong Liu Peng-Fei Shen Xin Tang Guang-Xi Sun Xing-Ming Zhang Jun-Ru Chen Kun-Peng Shu Ming Shi Hao Zeng |
spellingShingle |
Jin-Ge Zhao Jian-Dong Liu Peng-Fei Shen Xin Tang Guang-Xi Sun Xing-Ming Zhang Jun-Ru Chen Kun-Peng Shu Ming Shi Hao Zeng Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study Asian Journal of Andrology abiraterone; antiandrogen; castration-resistant prostate cancer; flutamide |
author_facet |
Jin-Ge Zhao Jian-Dong Liu Peng-Fei Shen Xin Tang Guang-Xi Sun Xing-Ming Zhang Jun-Ru Chen Kun-Peng Shu Ming Shi Hao Zeng |
author_sort |
Jin-Ge Zhao |
title |
Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study |
title_short |
Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study |
title_full |
Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study |
title_fullStr |
Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study |
title_full_unstemmed |
Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study |
title_sort |
prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study |
publisher |
Wolters Kluwer Medknow Publications |
series |
Asian Journal of Andrology |
issn |
1008-682X 1745-7262 |
publishDate |
2018-01-01 |
description |
Even in the era of novel targeted agents, switching to a second-line nonsteroidal antiandrogen (NSAA) is still widely used in treating metastatic castration-resistant prostate cancer (mCRPC), especially in undeveloped countries. However, whether prior treatment with a second-line NSAA would impact the efficacy of abiraterone acetate (Abi) remains uncertain. In the current study, 87 mCRPC patients treated with Abi were analyzed. Among them, 21 were treated with a second-line NSAA (from bicalutamide to flutamide) before receiving abiraterone, while the remaining 66 received Abi directly. Therapeutic efficacy of Abi was compared between those with and without prior second-line NSAA using Kaplan–Meier curves, log-rank test, and Cox regression models. The therapeutic efficacy of Abi was similar between those with or without the prior switching treatment of flutamide, in terms of either prostate-specific antigen progression-free survival (PSA-PFS, 5.5 vs 5.6 months, P = 0.967), radiographic progression-free survival (rPFS, 12.8 vs 13.4 months, P = 0.508), overall survival (OS, not reached vs 30.6 months, P = 0.606), or PSA-response rate (71.4% [15/21] vs 60.6% [40/66], P = 0.370). This is the first time that the impact of prior switching of treatment to a second-line NSAA on the efficacy of Abi in mCRPC patients has been addressed. Our data support that, use of prior sequential bicalutamide and flutamide does not seem to preclude response to abiraterone, although larger cohort studies and, ideally, a randomized controlled trial are needed. These findings will facilitate doctors' decision-making in the treatment of mCRPC patients, especially for those with previous experience of switching NSAA second-line treatments in the clinic. |
topic |
abiraterone; antiandrogen; castration-resistant prostate cancer; flutamide |
url |
http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=6;spage=545;epage=550;aulast=Zhao |
work_keys_str_mv |
AT jingezhao priorswitchingtoasecondlinenonsteroidalantiandrogendoesnotimpactthetherapeuticefficacyofabirateroneacetateinpatientswithmetastaticcastrationresistantprostatecancerarealworldretrospectivestudy AT jiandongliu priorswitchingtoasecondlinenonsteroidalantiandrogendoesnotimpactthetherapeuticefficacyofabirateroneacetateinpatientswithmetastaticcastrationresistantprostatecancerarealworldretrospectivestudy AT pengfeishen priorswitchingtoasecondlinenonsteroidalantiandrogendoesnotimpactthetherapeuticefficacyofabirateroneacetateinpatientswithmetastaticcastrationresistantprostatecancerarealworldretrospectivestudy AT xintang priorswitchingtoasecondlinenonsteroidalantiandrogendoesnotimpactthetherapeuticefficacyofabirateroneacetateinpatientswithmetastaticcastrationresistantprostatecancerarealworldretrospectivestudy AT guangxisun priorswitchingtoasecondlinenonsteroidalantiandrogendoesnotimpactthetherapeuticefficacyofabirateroneacetateinpatientswithmetastaticcastrationresistantprostatecancerarealworldretrospectivestudy AT xingmingzhang priorswitchingtoasecondlinenonsteroidalantiandrogendoesnotimpactthetherapeuticefficacyofabirateroneacetateinpatientswithmetastaticcastrationresistantprostatecancerarealworldretrospectivestudy AT junruchen priorswitchingtoasecondlinenonsteroidalantiandrogendoesnotimpactthetherapeuticefficacyofabirateroneacetateinpatientswithmetastaticcastrationresistantprostatecancerarealworldretrospectivestudy AT kunpengshu priorswitchingtoasecondlinenonsteroidalantiandrogendoesnotimpactthetherapeuticefficacyofabirateroneacetateinpatientswithmetastaticcastrationresistantprostatecancerarealworldretrospectivestudy AT mingshi priorswitchingtoasecondlinenonsteroidalantiandrogendoesnotimpactthetherapeuticefficacyofabirateroneacetateinpatientswithmetastaticcastrationresistantprostatecancerarealworldretrospectivestudy AT haozeng priorswitchingtoasecondlinenonsteroidalantiandrogendoesnotimpactthetherapeuticefficacyofabirateroneacetateinpatientswithmetastaticcastrationresistantprostatecancerarealworldretrospectivestudy |
_version_ |
1725045428058062848 |